Arvinas (ARVN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $2.58
- Estimate
- -$0.29
- Surprise
- +1000.0%
- Revenue (period 2026-06-30)
- $249.7M
- Score at report (before → after)
- 5.0 → 6.4/10
Revenue source: xbrl.
How the report landed
Arvinas (ARVN) beat the -$0.29 estimate with adjusted EPS of $2.58 — a large 1000.0% upside surprise. TrendMatrix's engine moved from Sell (5.0/10) to Hold at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARVN Hold at 6.1/10.
3 of the last 4 quarters beat the estimate; this quarter's +1000.0% surprise compares with a +240.1% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0)
- Negative momentum
- Below 200-MA, MA slope -4.7%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.31
- Price target
- $12.12
- Stop
- $7.00
- Upside to target
- +65.8%
- Reward-to-risk
- 7.4:1
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
ARVN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $478.0M
- P/E (fwd)
- -2.3
- P/E (ttm)
- 28.1
- 52-week range
- $6.97–$14.51
- Off 52-week high
- 49.6%
- RSI (14)
- 30
- Volume vs avg
- 0.65×
- Score today
- 6.1/10